Abstract:Loss-of-function mutations in methyl-CpG binding protein 2 (MECP2) cause Rett syndrome, a postnatal neurodevelopmental disorder that occurs in ~1/10,000 live female births. MeCP2 binds to methylated cytosines across genomic DNA and recruits various partners to regulate gene expression. MeCP2 has been shown to repress transcription in vitro and interacts with co-repressors such as the Sin3A and NCoR complexes. Based on these observations, MeCP2 has been largely considered as a repressor of transcription. However, a mouse model of RTT displays many down-regulated genes, and those same genes are up-regulated in a MECP2 duplication mouse model. Furthermore, TCF20, which has been associated with transcriptional activation, have recently been identified as a protein interactor of MeCP2. These data broaden the potential functions of MeCP2 as a regulator of gene expression. Yet, the molecular mechanisms underlying MeCP2-dependent gene regulation remain largely unknown. Here, using a human MECP2 gain-of-function Drosophila model, we screened for genetic modifiers of MECP2-induced phenotypes. Our approach identified several subunits of the Drosophila super elongation complex, a P-TEFb containing RNA polymerase II (RNA pol II) elongation factor required for the release of promoter-proximally paused RNA pol II, as genetic interactors of MECP2. We discovered that MeCP2 physically interacts with the SEC in human cells and in the mouse brain. Furthermore, we found that MeCP2 directly binds AFF4, the scaffold of the SEC, via the transcriptional repression domain. Finally, loss of MeCP2 in the mouse cortex caused reduced binding of AFF4 specifically on a subset of genes involved in the regulation of synaptic function, which also displayed the strongest decrease in RNA pol II binding in the genebody. Taken together, our study reveals a previously unrecognized mechanism through which MeCP2 regulates transcription, providing a new dimension to its regulatory role in gene expression.

MeCP2 Promotes Endothelial-to-mesenchymal Transition in Human Endothelial Cells by Downregulating BMP7 Expression

Methyl-CpG-binding Protein 2 Drives the Furin/TGF-β1/Smad Axis to Promote Epithelial–mesenchymal Transition in Pancreatic Cancer Cells

Methyl-CpG-binding Domain 3 Inhibits Epithelial–mesenchymal Transition in Pancreatic Cancer Cells Via TGF-β/Smad Signalling

MeCP2 inhibits cell functionality through FoxO3a and autophagy in endothelial progenitor cells

Mecp2 Inhibits Proliferation And Migration Of Breast Cancer Via Suppression Of Epithelial-Mesenchymal Transition

Exosomal miR-218 derived from mesenchymal stem cells inhibits endothelial-to-mesenchymal transition by epigenetically modulating of BMP2 in pulmonary fibrosis

MeCP2 Drives Hepatocellular Carcinoma Progression Via Enforcing HOXD3 Promoter Methylation and Expression Through the HB-EGF/EGFR Pathway.

MeCP2-421-mediated RPE epithelial-mesenchymal transition and its relevance to the pathogenesis of proliferative vitreoretinopathy.

MeCP2-mediated epigenetic regulation in senescent endothelial progenitor cells

BMP4 promotes metastasis of hepatocellular carcinoma by an induction of epithelial–mesenchymal transition via upregulating ID2

MeCP2 Mediated Dysfunction in Senescent EPCs.

A Central Role for MeCP2 in the Epigenetic Repression of Mir-200C During Epithelial-to-mesenchymal Transition of Glioma.

MECP2 Promotes Cell Proliferation by Activating ERK1/2 and Inhibiting P38 Activity in Human Hepatocellular Carcinoma HEPG2 Cells.

Epigenetic reader MeCP2 repressed WIF1 boosts lung fibroblast proliferation, migration and pulmonary fibrosis

MeCP2 Interacts with the Super Elongation Complex to Regulate Transcription

Transcriptional Inhibition of the Mecp2 Promoter by MeCP2E1 and MeCP2E2 Isoforms Suggests Negative Auto-Regulatory Feedback that can be Moderated by Metformin

TGF--mediated Endothelial to Mesenchymal Transition (EndMT) and the Functional Assessment of EndMT Effectors using CRISPR/Cas9 Gene Editing

Emerging physiological and pathological roles of MeCP2 in non-neurological systems

MeCP2 Promotes Gastric Cancer Progression Through Regulating FOXF1/Wnt5a/β-Catenin and MYOD1/Caspase-3 Signaling Pathways.

Association between MeCP2 and Smad7 in the pathogenesis and development of pathological scars

TGF-β-mediated Endothelial to Mesenchymal Transition (EndMT) and the Functional Assessment of EndMT Effectors using CRISPR/Cas9 Gene Editing.